Detalhe da pesquisa
1.
Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Int J Clin Oncol
; 27(4): 684-694, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089459
2.
Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.
BMC Cancer
; 20(1): 684, 2020 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32698781
3.
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Target Oncol
; 19(2): 181-190, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427280
4.
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
Sci Rep
; 13(1): 2433, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765099
5.
Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.
J Clin Med
; 11(8)2022 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35456340
6.
Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study.
J Gastrointest Oncol
; 13(6): 2769-2778, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36636083
7.
Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.
Clin Med Insights Oncol
; 16: 11795549221137135, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36408335
8.
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Pancreas
; 49(4): 574-578, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32282772
9.
Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab.
Int Cancer Conf J
; 9(1): 28-31, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31950014
10.
Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
Sci Rep
; 13(1): 11935, 2023 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488181